About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 404 record(s)
Req # A-2022-000568
Reports or briefings discussing national security risks posed by underfunding of mental healthcare services. Limited to or from director level and above. January 1, 2020 to August 8, 2022.Organization: Health Canada
August 2022
Req # A-2017-001468
Adverse Drug Reactions (ADRs) for PANTOPRAZOLE SODIUM. Report numbers: E2B_01380857, E2B_01387851, E2B_01393344, E2B_01393381, E2B_01393401, E2B_01393424, E2B_01393430, E2B_01397498, E2B_01399399, E2B_01399517, E2B_01399528, E2B_01399543, E2B_01399552, E2B_01401642, E2B_01401647, E2B_01401654, E2B_01403779, E2B_01403781, E2B_01403783, E2B_01403792, E2B_01403794, E2B_01405655, E2B_01405659, E2B_01405663, E2B_01407198, E2B_01407879, E2B_01412413, E2B_01412727, E2B_01415415, E2B_01416813.Organization: Health Canada
August 2022
Req # A-2019-001878
Adverse Drug Reactions (ADRs) for NICODERM. Report numbers: 000082489, 000082490, 000082762, 000124742, 000142959,000149041, 000162584, 000167061,000168635, 000176829, 000179810, 000180288, 000183685, 000184306, 000193630, 000214690, 000222530, 000226480, 000305248, 000311145, 000329610, 000354382, 000356000, 000392031, 000466455, 000632284, 000673373, 000673375, 000715107.Organization: Health Canada
August 2022
Req # A-2020-000012
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_02519891, E2B_02519892, E2B_02629603, E2B_02546210, E2B_02519895, E2B_02630187, E2B_02548384, E2B_02633072, E2B_02519896, E2B_02519904, E2B_02641090, E2B_02519908, E2B_02519915, E2B_02067663, E2B_02520126.Organization: Health Canada
August 2022
Req # A-2020-000018
Adverse Drug Reactions (ADRs). Report numbers: E2B_02555912, E2B_02551753, E2B_01658565, 000707755, 000713270, E2B_01736031, E2B_01853319, E2B_01878659, E2B_01893360, E2B_01896759, E2B_01893073, E2B_01944584.Organization: Health Canada
August 2022
Req # A-2020-000531
Adverse Drug Reaction (ADR). Report number: E2B_03068591.Organization: Health Canada
August 2022
Req # A-2020-000905
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-109574-918.Organization: Health Canada
August 2022
Req # A-2020-001148
Adverse Drug Reactions (ADRs). Report numbers: E2B_02812639, E2B_02637577, E2B_02876395, E2B_02885467, E2B_02973620, E2B_03074834, E2B_03077865, E2B_03150308, E2B_02558497, E2B_03196066, E2B_03198278, E2B_03207460, E2B_00783428, E2B_00783376.Organization: Health Canada
August 2022
Req # A-2020-001439
Adverse Drug Reactions (ADRs). Report numbers: E2B_02783988, E2B_02812102, E2B_02786720, E2B_02790685, E2B_02791398, E2B_02791432, E2B_02794085, E2B_02797871, E2B_02802751, E2B_02839388, E2B_02820586, E2B_02821148, E2B_02833294, E2B_02836714, E2B_02853096, E2B_02853368, E2B_02854638, E2B_02830914, E2B_02855029, E2B_02837093.Organization: Health Canada
August 2022
Req # A-2020-001474
Adverse Drug Reactions (ADRs) for Leflunomide. Report numbers: E2B_03079325, E2B_03079327, E2B_03079341, E2B_03015870, E2B_03079369, E2B_03079973, E2B_03021133, E2B_03080114, E2B_03080337, E2B_03080357, E2B_03080393, E2B_03080435, E2B_03092550, E2B_03080486, E2B_03080611, E2B_03080657, E2B_03080690, E2B_03135245, E2B_03135400, E2B_03011749.Organization: Health Canada
August 2022